Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Galmed Pharmaceuticals Ltd

GLMD
Current price
0.37 USD -0.029 USD (-7.23%)
Last closed 0.39 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 328 138 USD
Yield for 12 month -91.37 %
1Y
3Y
5Y
10Y
15Y
GLMD
21.11.2021 - 28.11.2021

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Tiomkin Street, Tel Aviv, Israel, 6578317

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-31 000 USD

Last Year

-35 000 USD

Current Quarter

-6 000 USD

Last Quarter

Key Figures GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -7 461 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -28.22 %
PEG Ratio
Return On Equity TTM -50.63 %
Wall Street Target Price 1 USD
Revenue TTM
Book Value 2.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.5 USD
Diluted Eps TTM -2.5 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GLMD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 15.05.2023
Dividend Date

Stock Valuation GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 1.3509
Price Book MRQ 0.1817

Financials GLMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GLMD

For 52 weeks

0.26 USD 5 USD
50 Day MA 0.37 USD
Shares Short Prior Month 83 762
200 Day MA 0.45 USD
Short Ratio 1.28
Shares Short 72 782
Short Percent 1.26 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics